C
Carlos Caldas
Researcher at University of Cambridge
Publications - 573
Citations - 86546
Carlos Caldas is an academic researcher from University of Cambridge. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 122, co-authored 547 publications receiving 73840 citations. Previous affiliations of Carlos Caldas include Institute of Cancer Research & University of Münster.
Papers
More filters
Journal ArticleDOI
Microarray segmentation methods significantly influence data precision
TL;DR: It is shown that the method of segmentation significantly affects the precision of the microarray data, and the histogram method gave the lowest variability across replicate spots compared to other methods, and had the lowest pixel-to-pixel variability within spots.
Journal ArticleDOI
Molecular classification of solid tumours: towards pathway-driven therapeutics
Charles Swanton,Carlos Caldas +1 more
TL;DR: These developments are gradually leading to a change in emphasis of early clinical trials to a therapeutic model guided by the molecular classification of tumours, and functional genomic studies using RNA interference-screening tools promises to improve the classification of solid tumours by probing the relevance of each gene to tumour phenotype.
Journal ArticleDOI
ESR1 gene amplification in breast cancer: a common phenomenon?
Lindsay Brown,Jeremy Hoog,Suet-Feung Chin,Suet-Feung Chin,Yu Tao,Abd Alnaser Zayed,Koei Chin,Andrew E. Teschendorff,Andrew E. Teschendorff,John Quackenbush,John C. Marioni,John C. Marioni,Samuel Leung,Charles M. Perou,Torsten O. Neilsen,Matthew J. Ellis,Joe W. Gray,Philip S. Bernard,David G. Huntsman,David G. Huntsman,Carlos Caldas,Carlos Caldas +21 more
TL;DR: The present work presents a novel and scalable approaches that allow for real-time, scalable, and reproducible characterization of the H2O2 “spatially checkpoints” in the response to chemotherapy-related cancers.
Journal ArticleDOI
Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.
TL;DR: Aurora kinase A outperforms other proliferation markers as an independent predictor of BCSS in ER-positive breast cancer and has the potential for use in routine clinical practice.
Journal ArticleDOI
Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours.
Hilal Özdağ,Sarah J. Batley,A Försti,A Försti,N G Iyer,Yataro Daigo,J Boutell,Mark J. Arends,Bruce Ponder,Tony Kouzarides,Carlos Caldas +10 more
TL;DR: Data suggest that neither CBP or PCAF gene is commonly inactivated in human epithelial cancers.